Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Upgraded by Wall Street Zen

Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued research reports about the stock. Lake Street Capital assumed coverage on shares of Verrica Pharmaceuticals in a research note on Thursday, August 27th. They set a “buy” rating and a $9.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Verrica Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $12.67.

Verrica Pharmaceuticals Price Performance

Shares of VRCA opened at $4.37 on Friday. The business’s 50-day moving average is $5.06 and its 200-day moving average is $5.70. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.45 and a quick ratio of 1.33. The company has a market capitalization of $75.08 million, a price-to-earnings ratio of -2.62 and a beta of 1.49. Verrica Pharmaceuticals has a fifty-two week low of $3.28 and a fifty-two week high of $9.82.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Armistice Capital LLC raised its stake in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 75.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,118,925 shares of the company’s stock after buying an additional 479,732 shares during the period. Armistice Capital LLC owned 7.00% of Verrica Pharmaceuticals worth $9,298,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company’s work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options.

Verrica’s lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older.